MOTS-c Storage and Stability: What Studies Report

Answer first: what the published record does and does not contain

The most common search around this topic — how long is MOTS-c good for after reconstitution — does not have an answer in the peer-reviewed MOTS-c literature reviewed for this page. The papers that exist on this mitochondrial-derived peptide are pharmacology and mechanism papers. They describe what happened in cells and animals, not how long a vial of dissolved peptide retained its purity on a bench or in a refrigerator. No stability-indicating assay, no accelerated-degradation study and no shelf-life determination for MOTS-c was identified among the verified sources.

That gap matters, because it means any confident number circulating online ("X days at 4 °C", "Y weeks frozen") is not traceable to a MOTS-c stability publication. What can be summarised responsibly is two things: first, what the MOTS-c literature establishes about the molecule itself; second, what the general peptide-stability literature describes about the physical and chemical processes that degrade small peptides in the lyophilized and dissolved states. This page keeps those two categories clearly separated and does not merge class-level chemistry into MOTS-c-specific claims.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision. Nothing here describes handling for personal use.

What MOTS-c is, in the terms the literature uses

MOTS-c was described in a 2015 report as a 16-amino-acid peptide encoded within the mitochondrial genome, and researchers reported that it promoted metabolic homeostasis and reduced diet-induced obesity and insulin resistance in mice (2015, Cell Metabolism). Later reviews collected the expanding literature on the peptide and its proposed roles in metabolic regulation (2023 review) (2023 review on metabolic disorders).

Its small size is the single most relevant fact for a stability discussion. A 16-residue peptide has no tertiary fold to protect labile bonds, no disulfide scaffold in the sense of larger proteins, and a high surface-to-mass ratio, so it behaves in solution more like a small molecule with several reactive side chains than like a globular protein. Degradation of such peptides is, in the general analytical literature, chemical (bond-level) as much as physical (aggregation or adsorption).

The functional studies also illustrate why intact sequence matters. In 2024, researchers reported that MOTS-c bound and activated casein kinase 2 (CK2) directly in the context of skeletal muscle function (2024, iScience). A binding-dependent mechanism is, in principle, sensitive to sequence modification: oxidation, deamidation or truncation can change affinity even when total peptide mass in a vial is unchanged. None of the verified papers tested degraded MOTS-c against intact MOTS-c, so this remains a general inference about peptide pharmacology rather than a measured MOTS-c result.

Lyophilized versus reconstituted: the general chemistry

Across peptide analytical chemistry, the difference between a dry lyophilized cake and an aqueous solution is the dominant variable in stability. Water is both a reactant and a mobility medium. In the dry state, residual moisture is low, molecular mobility is restricted, and the main degradation routes described in the literature are slow oxidation (if oxygen and light are present) and physical changes to the cake. Once water is added, several reactions that were effectively frozen out become kinetically available at once.

The degradation pathways most often catalogued for peptides in solution include:

• Hydrolysis of peptide bonds, strongly pH- and temperature-dependent.
• Oxidation of susceptible side chains, accelerated by dissolved oxygen, trace metals and light exposure.
• Deamidation and isomerisation at asparagine and aspartate-containing motifs, again pH-dependent.
• Aggregation and precipitation, which can remove peptide from solution without changing the chemistry of what remains dissolved.
• Surface adsorption onto glass or plastic, which lowers effective concentration in dilute solutions.

These are class-level statements from peptide formulation science. They are not measurements on MOTS-c, and the rate of each process for MOTS-c specifically in any given buffer was not reported in the verified literature.

Temperature, freeze-thaw, light and container: what stability science generally describes

The table below separates what general peptide-stability literature describes from what the MOTS-c-specific verified sources actually contain.

The pattern in that right-hand column is the honest summary of the current record. The MOTS-c literature has moved quickly on biology and not at all, publicly, on formulation.

Why MOTS-c papers do not answer the shelf-life question

Reading the verified body of work makes the reason clear: these were biological questions. A 2022 study reported that MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model (2022, Pharmacological Research). In 2024, researchers reported that MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (2024, AJP-Endocrinology and Metabolism), while a separate group reported that MOTS-c promoted muscle differentiation in cultured cells (2022, Peptides). Oncology and virology work followed the same pattern: a 2024 paper reported suppression of ovarian cancer progression through a USP7–LARS1 mechanism (2024, Advanced Science), and another reported an antiviral role during hepatitis B virus infection linked to mitochondrial remodelling (2024, Gut). A 2025 report described prevention of pancreatic islet cell senescence in a diabetes model (2025, Experimental & Molecular Medicine), and a 2024 study reported MOTS-c involvement in mitigating radiation-induced lung injury alongside pyrroloquinoline quinone (2024, Journal of Agricultural and Food Chemistry).

In each case the experimental peptide was a research reagent prepared for that experiment. Journals of this type report outcome measures; they do not typically publish stability-indicating chromatography on the reagent, and none of these abstracts did.

How a stability question is answered in the laboratory

For readers trying to understand what a real answer would look like, the general methodology in peptide analytics is worth outlining, because it explains why a single number is rarely meaningful:

1. A stability-indicating assay is validated first — usually reversed-phase HPLC with UV detection, able to separate the intact peptide from its degradation products, often with mass spectrometry to identify what the new peaks are.
2. Stress conditions are applied deliberately — elevated temperature, extremes of pH, oxidising agents, light exposure and freeze-thaw cycles — to generate degradants and prove the assay can see them.
3. Real-time and accelerated storage arms run in parallel, with timepoints sampled and purity tracked against a defined acceptance threshold.
4. Results are reported as condition-specific: a purity retention figure is only valid for the stated concentration, buffer, pH, container, headspace and temperature.

That last point is why transplanted numbers are unreliable. A stability result for one peptide at one concentration in one buffer does not transfer to another peptide, and it does not transfer to the same peptide at a different concentration or pH. Because no such dataset for MOTS-c was identified here, a defensible statement is simply that the shelf life of a reconstituted MOTS-c solution has not been characterised in the published literature reviewed.

Bioactivity as a separate axis from chemical purity

Chemical intactness and biological activity are measured differently, and the MOTS-c literature is a useful illustration. The 2024 CK2 work reported direct binding as the proximate mechanism (2024, iScience), and reviews have described intracellular and nuclear localisation among the peptide's reported behaviours (2023 review). In principle, a solution could show acceptable purity by chromatography while a fraction of the material has been chemically modified at a residue that matters for binding — or, conversely, could lose measured concentration through surface adsorption while the remaining peptide is fully intact. The verified sources did not test either scenario for MOTS-c, so this remains an explanation of why "still good" is an ambiguous phrase rather than a finding about the peptide.

Regulatory and status context

MOTS-c is not an approved drug product in the United States or European Union. There is no marketed formulation, and therefore no regulator-reviewed stability package, no approved label storage statement and no assigned in-use period — the documents that would ordinarily answer a storage question for a medicine simply do not exist for this peptide. Material referenced in the literature is research-grade, supplied for laboratory investigation, and the studies cited above were animal and cell experiments rather than clinical trials.

Limits of this summary

• No MOTS-c stability study was identified in the verified sources; the absence of data is the finding, not a low or high stability estimate.
• General peptide chemistry is class-level. Hydrolysis, oxidation, deamidation, aggregation and adsorption are well described for peptides broadly; their rates for MOTS-c under any specific condition were not reported.
• Biological findings do not imply shelf life. The metabolic, muscle, islet, oncology and antiviral results summarised above were outcome studies in cells and animals.
• Human data are limited. The verified literature is preclinical and review material; no clinical pharmacokinetic or in-use stability data were available.
• Nothing here is a handling instruction. This page describes published science and general laboratory concepts only.

References

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology. Endocrinology and Metabolism, 2024)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)